Science Wiki

Escherichia coli (abbreviated E. coli) is a Gram-negative, facultatively anaerobic, non-sporulating, rod-shaped gammaproteobacterium (family *Enterobacteriaceae*, dimensions ~1.0 × 2.0 μm) that colonizes the lower gastrointestinal tract of warm-blooded vertebrates within hours of birth. While certain virulent pathotypes acquired via horizontal gene transfer cause severe enteric, urinary, and systemic infections, commensal strains constitute a beneficial component of the human gut microbiome (synthesizing vitamin K₂ and resisting pathogen colonization), and laboratory derivative strains (such as K-12 MG1655 and B/BL21) serve as the primary model organism for systems biology, molecular genetics, and industrial biomanufacturing.

Because of its 20-minute doubling time in rich media at 37°C, chemically defined nutritional requirements, and tractable genome, *E. coli* was the experimental chassis used to discover the genetic code, the mechanism of semi-conservative DNA replication, operon-mediated gene expression, restriction enzymes, and recombinant DNA cloning.

Core vs. Pan-Genome Plasticity

The benign laboratory reference strain *E. coli* K-12 MG1655 (sequenced by Frederick Blattner and colleagues in 1997) possesses a single circular chromosome of 4,641,652 base pairs (GC content 50.8%) encoding approximately 4,300 proteins and 109 structural RNAs. However, comparative genomics across thousands of environmental and clinical isolates reveals an open pan-genome: while any individual *E. coli* strain carries ~4,200 to 5,500 genes (up to 5.5 Mb in enterohemorrhagic strains), only ~2,000 genes constitute the conserved core genome shared by all strains. The remaining accessory genome is continuously exchanged via conjugative plasmids, transposons, integrative conjugative elements, and bacteriophage transduction.

Replication Fidelity and Stress-Induced SOS Mutagenesis

Under unstressed exponential growth, replisome Pol III holoenzyme synthesis coupled with 3'→5' ε-subunit proofreading and MutSLH methyl-directed mismatch repair maintains an exceptionally low spontaneous mutation rate of ~1 × 10⁻¹⁰ to 2 × 10⁻¹⁰ mutations per base pair per generation (~0.001 mutations per genome duplication).

However, when *E. coli* encounters sub-lethal antibiotic exposure (such as fluoroquinolones causing DNA double-strand breaks or β-lactams disrupting peptidoglycan synthesis) or UV irradiation, single-stranded DNA filaments coated with RecA trigger autocatalytic cleavage of the LexA repressor, activating the global SOS response (>40 genes). The SOS regulon upregulates low-fidelity, Y-family translesion synthesis polymerases—Pol IV (*dinB*) and Pol V (*umuDC*)—which lack proofreading activity and bypass replication-blocking lesions at the cost of a 100- to 1,000-fold transient spike in mutation rates (stress-induced mutagenesis), accelerating the emergence of antibiotic resistance alleles.

To maximize growth efficiency in fluctuating nutrient environments, *E. coli* couples transcription directly to metabolite sensing via operons—polycistronic gene clusters transcribed as a single mRNA from a shared promoter.

Boolean AND-Gate Logic of the *lac* Operon

Elucidated by François Jacob and Jacques Monod in 1961, the *lac* operon (*lacZYA*) encodes β-galactosidase (LacZ, which cleaves lactose into glucose and galactose and isomerizes lactose to allolactose), lactose permease (LacY), and galactoside O-acetyltransferase (LacA). The regulatory circuit operates as a molecular Boolean AND gate (Lactose PRESENT AND Glucose ABSENT):

1. Negative Control by the LacI Repressor (Lactose Sensor): In the absence of lactose, the homotetrameric LacI repressor binds with picomolar affinity to the primary operator (*O₁*) and auxiliary operators (*O₂*/*O₃*), looping the DNA and sterically blocking RNA polymerase initiation. When lactose enters the cell, a fraction is converted to 1,6-allolactose, which binds allosterically to LacI monomers, inducing a conformational shift that lowers operator affinity by ~1,000-fold and releases the repressor.
2. Positive Control by cAMP–CRP (Glucose Sensor): Even when LacI is unbound, the native *lac* promoter exhibits weak RNA polymerase binding. When extracellular glucose is abundant, import via the phosphotransferase system (PTS) dephosphorylates EIIA^Glc, which inhibits adenylate cyclase and keeps intracellular cyclic AMP (cAMP) low (catabolite repression) while directly blocking LacY permease (inducer exclusion). Only when glucose is exhausted does phosphorylated EIIA^Glc~P activate adenylate cyclase, elevating cAMP to form the cAMP–CAP (CRP) complex, which bends DNA by ~90° upstream of the promoter and recruits the α-CTD of RNA polymerase to drive 50-fold higher transcription.

When cultured in media containing both glucose and lactose, *E. coli* displays a biphasic diauxic growth curve: cells consume glucose exclusively during the first exponential phase, enter a 30–45 minute lag phase upon glucose exhaustion to transcribe *lacZYA*, and resume a second exponential growth phase powered by lactose hydrolysis.

As a facultative anaerobe controlled by the oxygen-sensing transcription factor FNR (which contains a labile [4Fe-4S]²⁺ cluster oxidized and disassembled by O₂) and the two-component ArcAB quinone-redox sensor, *E. coli* dynamically reconfigures its bioenergetic pathways across three hierarchical regimes:

• Aerobic Respiration (O₂ Present): Carbon flows through glycolysis and the complete oxidative citric acid cycle (TCA cycle). Electrons from NADH and FADH₂ pass through ubiquinone to terminal cytochrome *bo*₃ (high O₂) or cytochrome *bd* (microaerobic, high O₂ affinity) oxidases, generating a proton-motive force that drives F₁F_O-ATP synthase (~26–32 ATP per glucose).
• Anaerobic Respiration (O₂ Absent, Alternative Electron Acceptors Present): FNR and NarXL repress aerobic oxidases and induce alternative respiratory reductases that transfer electrons via menaquinone/demethylmenaquinone to exogenous terminal acceptors in strict order of redox potential (E₀'): nitrate (NO₃⁻ → NO₂⁻, E₀' = +433 mV), DMSO (+160 mV), TMAO (+130 mV), or fumarate (fumarate → succinate, E₀' = +31 mV).
• Mixed-Acid Fermentation (No External Electron Acceptors): The TCA cycle splits into a branched, non-cyclic biosynthetic pathway (oxidative branch to α-ketoglutarate; reductive branch to succinate), and pyruvate formate-lyase (PflB) cleaves pyruvate into acetyl-CoA and formate. To maintain redox balance (regenerating NAD⁺ from glycolytic NADH), *E. coli* excretes a stoichiometric mixture of acetate, ethanol, D-lactate, succinate, and H₂ + CO₂ (via formate hydrogenlyase), yielding net 2–3 ATP per glucose.

Whereas commensal and laboratory strains lack virulence determinants, pathogenic *E. coli* strains have acquired mobile Pathogenicity Islands (PAIs), virulence plasmids, and prophage toxins via horizontal gene transfer:

EHEC Shiga Toxin Ribosomal Inactivation

Enterohemorrhagic *E. coli* (EHEC, archetypally serotype O157:H7, infectious dose <50 CFU) secretes phage-encoded Shiga toxins (Stx1 and Stx2). The pentameric B-subunit binds globotriaosylceramide (Gb3) glycolipids highly expressed on human colonic microvascular and renal glomerular endothelial cells. Following retrograde transport through the Golgi and endoplasmic reticulum, the catalytic A1 subunit acts as an RNA N-glycosidase that depurinates a single invariant adenine residue (A4324) on the α-sarcin/ricin loop of the 28S ribosomal RNA in the 60S ribosomal subunit. This stops aminoacyl-tRNA elongation, halts translation, and triggers endothelial apoptosis, microvascular thrombosis, thrombocytopenia, and renal failure (Hemolytic Uremic Syndrome). Because fluoroquinolones and trimethoprim-sulfamethoxazole induce the bacterial SOS response—which excises the Stx prophage and massively amplifies Shiga toxin synthesis—antibiotics are clinically contraindicated in EHEC O157:H7 infection.

EPEC Type III Secretion and Actin Pedestals

Enteropathogenic *E. coli* (EPEC) uses the 35-kb Locus of Enterocyte Effacement (LEE) pathogenicity island to assemble a needle-like Type III Secretion System (T3SS) injectisome across the bacterial inner/outer membranes and the host lipid bilayer. EPEC translocates its own receptor—Tir (Translocated Intimin Receptor)—directly into the host enterocyte plasma membrane, where Tir adopts a hairpin topology and binds the bacterial outer-membrane adhesin Intimin. Host tyrosine kinase phosphorylation of Tir recruits Nck, N-WASP, and the Arp2/3 complex, nucleating dense F-actin polymerization directly beneath the bacterium to elevate it atop a 10 μm actin pedestal while effacing absorptive microvilli.

UPEC Adhesins and Intracellular Biofilm Pods

Uropathogenic *E. coli* (UPEC) resists hydrodynamic urine flow (~20–40 dyn/cm² shear stress) via catch-bond Type 1 pili tipped with the mannose-binding adhesin FimH, which locks more tightly under tensile shear to mannosylated uroplakin Ia/Ib plaques on bladder superficial umbrella cells. Invading UPEC proliferate inside the umbrella cell cytoplasm within biofilm-like Intracellular Bacterial Communities (IBCs) shielded from neutrophils and antibiotics, before filamenting and fluxing out to invade adjacent urothelial layers or ascending to the kidneys via P-fimbriae (PapG) binding to globoseries glycolipids.

Why are antibiotics contraindicated in *E. coli* O157:H7 (EHEC) infections?

In enterohemorrhagic *E. coli* (EHEC O157:H7), the genes encoding Shiga toxin (Stx1 and Stx2) reside inside a dormant lambdoid bacteriophage (prophage) integrated into the bacterial chromosome. Administering DNA-damaging or cell-wall-active antibiotics triggers the bacterial SOS stress response, which activates the prophage lytic cycle—causing the bacteria to produce and release massive quantities of Shiga toxin as they lyse, significantly increasing the risk of fatal Hemolytic Uremic Syndrome (HUS).

How does *E. coli* prioritize glucose over lactose during the diauxic shift?

*E. coli* uses dual control-theoretic regulation at the *lac* operon: when glucose is actively transported into the cell, the unphosphorylated PTS enzyme EIIA^Glc directly binds and inhibits LacY permease (blocking lactose entry, termed inducer exclusion) while failing to activate adenylate cyclase, keeping intracellular cAMP low so the cAMP–CRP activator complex cannot recruit RNA polymerase to the *lac* promoter until all glucose is consumed.

Why are laboratory *E. coli* K-12 and BL21 strains safe for biotechnology?

Laboratory strains *E. coli* K-12 (isolated in 1922) and B/BL21 have been subcultured for decades and carry permanent genetic deletions that eliminate the O-antigen lipopolysaccharide side chains, the K1 capsular polysaccharide, type III secretion systems, and enterotoxins. Without an O-antigen or capsule, K-12 and BL21 are immediately lysed by human serum complement and cannot colonize the human gastrointestinal tract.